Technologies
Regenerative Medicine
| Publication Date | April 2008 |
| Publisher | Global Industry Analysts |
| Product Type | Report |
| Pages | 383 |
| ISBN Number | not applicable |
| Product Code | GIA00233 |
Price
£2,555.00
approximately: $3,949 | €3,036
approximately: $3,949 | €3,036
Order above formats by FAX
Summary
This report analyzes the worldwide markets for Regenerative Medicine in Millions of US$. The report provides separate comprehensive analytics for the US, Japan, and Europe. Annual forecasts are provided for each region for the period of 2003 through 2015. The report profiles 106 companies including many key and niche players worldwide such as BioVest International, Inc., Curis, Inc., Cytori Therapeutics, Inc., DeveloGen AG, Forticell Bioscience, Inc., Geron Corporation, Human Genome Sciences, Inc., IsoTis, Inc., Kiadis Pharma B.V., LifeCell Corporation, Osiris Therapeutics, Inc., Tepha Inc., and TiGenix N.V. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Contents
- I. Introduction, Methodology & Product Definitions
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
- II. Executive Summary
- 1.Industry Overview
- Regenerative Medicine - the past, the Present, & the Future
- Another Revolution in the Making?
- Conventional Chemical Medicine vs Regenerative Medicine
- The Need for Regenerative Medicine
- Regenerative Medicine Throws in Several New Therapies
- What's in Store?
- Regenerative Medicine to Arrest Ageing
- Thriving on an Aging World Population
- Faster Healing Process
- Regenerative Medicine to Overcome Donor Organs Shortage
- Possible Scenarios
- Stem Cell Research - Not Just Another Medical Advancement
- Key Issues at Play
- Market Potential
- Regenerative Medicine in Bone and Joint Applications
- US Corners a Lion's Share
- Growth Drivers
- Trends & Issues
- Biomaterials Sought after in Regenerative Medicine
- Upbeat Market for Cell-based Tissue Engineering
- Progenitor Cell Therapy to Witness No Holds Barred Growth
- Players Embrace Automation in Production Facilities
- Contract Manufacturing, a Growing Sector
- Investors Wary of Funding Regenerative Medicine
- Regenerative Medicine Field Lags behind due to Segregated Focus
- Challenges to Be Encountered by Tissue Engineering Companies
- Activity in the Field of Regenerative Medicine
- 2.Product Overview
- Regenerative Medicine Advances in Four Phases
- Human Substances
- Tissue Engineering
- Therapeutic Cloning
- Nanotechnology-Driven Biomaterials
- Types of Regenerative Medicine
- Type I - Regenerative Medicine
- Human Proteins and Genes are Drugs in Regenerative Medicine
- Type-2 Regenerative Medicine
- Therapies Based on Human Cells and Tissues
- Type-3 Regenerative Medicine
- Based on Embryonic Stem Cells
- The Opponents of the ESC Theory
- Embryonic Stem Cells - Shortcomings
- Type-4 Regenerative Medicine
- Based on Novel Materials / Material Science Advancements
- Overview of Major Regenerative Medicine Techniques
- Natural Regenerative Proteins
- Tissue Engineering Capable of Culturing Replacement Organs
- All about Stem Cells
- Adult Stem Cells
- Adult Stem Cell Research Eludes Ethical Dispute
- hESC - Highly Capable of Differentiating and Multiplying
- Stem Cell Research in Development of Regenerative Medicine
- Neural Stem Cell to Restore Memory Functioning
- Pancreatic Islet Cells to Control Blood Sugar in Diabetics
- Therapeutic Cloning to Cure Parkinson's
- 3.Regulatory Environment
- Regulatory Norms Governing ES Cell Research
- Milestones in the Human Embryonic Stem Cell Research: 2001
- Legality of ES Cell Use in Major Developed Nations
- 4.Technological Innovations / Breakthroughs
- Celprogen Launches 11 Cancer Stem Cells
- Biovest International Launches AutovaxID
- Stelic Institute Announces New Treatment Method for Acute Liver Failure
- TissueGene Initiates Phase 1 Clinical Trials for TG-C
- ISTO Announces FDA's IND Approval for Neocartilage Graft
- Cook Biotech Introduces Surgisis AFP Anal Fistula Plug
- Korean Scientists Make a Major Breakthrough in Stem Cell Lines
- Japanese Researchers Regenerate Jaw Bone
- Geron Researchers Differentiate Hepatocytes from hESCs
- Geron Demonstrates Potential of hESCs in Treatment of Parkinson's disease
- Geron Researches Cardiomyocytes for Heart Disease
- Endovasc Announces New Findings at Texas Heart Institute Research
- Geron and Celera Genomics Complete Characterization of Active Genes in hESCs
- Rockefeller University Develops Solution for Maintaining Plupotency in hESCs
- 5.Recent Industry Activity
- Cytori and Green Hospital Supply Ink Strategic Equity Deal
- RNL Bio Establishes Research Unit at Newcastle University
- Tengion Begins Third Phase II Clinical Trial of Neo-Bladder Augment
- Organogenesis Signs MoU with NTEC
- BioTime Establishes New Stem Cell Division
- Integra Life Sciences Acquires IsoTis, Inc.
- NovaThera and Gamida Join Hands for Developing Cell Therapeutics for Lung Regeneration
- Tigenix Teams up with Fidea to Develop Biological Joint Implants
- Scotland Plans to Build Center for Regenerative Medicine in Edinburgh
- Celmed BioSciences Merges with Kiadis
- Bayer Acquires Schering AG
- Genentech Files IND Application with FDA
- National Stem Cell Holding and Azurel Merge
- StemCells and Stem Cell Therapeutics in Licensing Agreement
- co.don Signs Distribution Agreement with Austrian Company
- Olympus to Increase Investment in Olympus-Cytori, Inc.
- Geron and University of Edinburgh in Collaboration for Development of hESCs
- Ortho-McNeil Acquires ColBar LifeScience
- CCMB to Establish Research Center for Regenerative Medicine
- Cambrex and Cytori Therapeutics in Strategic Alliance
- co.don Signs Distribution Agreement with XMEDICA
- NCRM Signs MoU with Eye Hospital for Occular Research
- Theregen Receives Funding from Sanderling Ventures
- Musculoskeletal Transplant Foundation Signs Research and Investment Agreements with ProChon Biotech
- Olympus and Cytori Therapeutics Establish Olympus-Cytori, Inc.
- StemCo Biomedical is now Aldagen, Inc.
- Healtheuniverse Establishes R&D Base in Singapore
- BioMimetic Receives FDA Approval for GEM 21S
- Gambro and Nephrogen in Research Partnership
- UC-Berkley Bags US$ 2.5 Million Grant from CIRM
- MacroPore Biosurgery Receives US$ 11 Million through Equity Placement
- World's third Largest Laboratory for Regenerative Medicine
- Ortec Forms a Joint Venture with HAPTO
- Curis Extends Agreement with Genentech
- Curis Strikes a Deal with Genentech
- Curis Collaborates with Wyeth Pharmaceuticals
- co.don Strikes a Deal with Bioengi Ltd
- StemCells Licenses Stem Cell Technology to ReNeuron
- Osiris Receives FDA Approval to Commence Stem Cell Trial for Knee Repair
- Geron Corporation and BRC Establish TA Therapeutics Limited
- Celmed BioSciences Pockets NewBiotics
- Celmed BioSciences Collaborates with Gambro BCT
- Ortec Collaborates with ESI
- BMPI in Alliance with Luitpold Pharmaceuticals
- BioVest International Enters into a Supply Agreement with Bioventix
- Geron Inks Two Licensing Agreements with Revivicor
- Geron Enters into a Licensing Agreement with P&G
- Roslin Institute, Geron, CXR Strike a Deal
- Geron Signs a Licensing Agreement with Xcellsyz
- Geron Inks a Pact with Merix
- Agreement between HGSI and GlaxoSmithKline
- MacroPore Biosurgery Sells off Bioresorbable Thin Film Product Line
- Jenapharm Divests Therapeutics Business
- Celmed BioSciences Divests Celmed USA
- Schering Extends Research Facility in Japan
- Stem Cell Research Gets Approval in California
- Accentia Acquires Majority Stake in BioVest
- DeveloGen Merges with Peptor
- DeveloGen Partners with Evotec OAI
- LifeCell Collaborates with NSCC
- LifeCell Corporation Accords with SHO
- Osiris Enters into a Licensing Agreement with JCR
- TiGenix Inks a Pact with IQL
- BioVest International Signs an Agreement with BioE, Inc
- PPL Therapeutics Divests Regenerative Medicine Business
- Osiris Bags EU Patent for Matter Composition in Adult, Human MSC
- J-TEC and Nagoya University Develop Cell Culture System
- Marubeni Takes a Minor Stake in GBS
- Tepha Develops New Biomaterials for Regenerative Medicine
- Gunze Inaugurates Regenerative Medicine Research Facility
- Geron Corporation and Exeter Life Sciences Establish stART Licensing, Inc
- Cambrex Establishes New Facility to Manufacture Cell Therapy
- 6.Focus on Select Global Players
- BioVest International, Inc. (US)
- Curis, Inc. (US)
- Cytori Therapeutics, Inc. (US)
- DeveloGen AG (Germany)
- Forticell Bioscience, Inc. (US)
- Geron Corporation (US)
- Human Genome Sciences, Inc. (US)
- IsoTis, Inc. (US)
- Kiadis Pharma B.V.
- LifeCell Corporation (US)
- Osiris Therapeutics, Inc. (US)
- Tepha Inc. (US)
- TiGenix N.V. (Belgium)
- 7.Global Market Perspective
- 1.Industry Overview
- III. Market
- 1.The United States
- A. Market Analysis
- Market Potential
- Regenerative Medicine in Bone and Joint Applications
- Regenerative Therapy - Best Fit for Joint Problems
- Millions of American Patients Put their Hope in Stem Cell Research
- US Witnesses Mixed Response for Government Support for hESC Research
- CBI's Human Tissue Products for Treating Liver Failure and Diabetes
- Market for Liver and Pancreas Transplantation
- Implantable Regenerative Products Take over Sports Medicine
- Key Players
- BioVest International, Inc.
- Curis, Inc.
- Cytori Therapeutics, Inc.
- Geron Corporation
- Human Genome Sciences, Inc.
- IsoTis, Inc.
- Osiris Therapeutics, Inc.
- Revivicor, Inc..
- Tepha Inc.
- Other Key Players & Activities
- Technological Developments
- Strategic Developments
- B. Market Analytics
- A. Market Analysis
- 2.Japan
- A. Market Analysis
- Market Potential
- Research Activity in Regenerative Medicine Field
- More Companies Eye the Regenerative Medicine Potential
- Competition Heats up behind Closed Doors
- Japanese Firms Need to Catch up with US and European Competitors
- Science Ministry Rolls out Regenerative Medicine Project
- Regenerative Medicine Exempted from Ban on Human Cloning
- Technological Developments
- Strategic Developments
- Developments in Recent past
- B. Market Analytics
- A. Market Analysis
- 3.Europe
- A. Market Analysis
- Germany
- Key Players
- co.don AG
- DeveloGen AG
- United Kingdom
- Belgium
- Select Player.
- TiGenix N.V.
- Strategic Developments
- B. Market Analytics
- A. Market Analysis
- 4.Review of Regenerative Medicine in Other Geographic Markets
- 4a.Canada
- University of Toronto - Spearheading Regenerative Medicine Research
- Strategic Developments
- 4b.Asia-Pacific
- China
- Substantial Government Support
- India
- CSIR- Leading the way in Regenerative Medicine Research
- High Growth Opportunities
- Australia
- Key Player
- Stem Cell Sciences
- South Korea
- Malaysia
- Singapore
- Strategic Developments
- 4c.Rest of World
- Argentina
- Israel
- Select Major Players
- Colbar R&D Ltd.
- ProChon Biotech Ltd..
- South Africa
- Strategic Development
- 1.The United States
- IV. Competitive Landscape
- List of Tables
- Table 1: World Recent past, Current & Future Market Analysis for Regenerative Medicine Products for Bone and Joint Applications by Geographic Region - US, Japan and Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
- Table 2: World Long-term Projections for Regenerative Medicine Products for Bone and Joint Applications by Geographic Region - US, Japan and Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 3: World 8-Year Perspective for Regenerative Medicine Products for Bone and Joint Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan and Europe for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
- Table 4: Prevalence of Various Diseases in the US
- Table 5: US Recent past, Current & Future Analysis for Regenerative Medicine Products for Bone and Joint Applications - Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
- Table 6: US Long-Term projections for Regenerative Medicine Products for Bone and Joint Applications - Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 7: Japanese Recent past, Current & Future Analysis for Regenerative Medicine Products for Bone and Joint Applications - Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
- Table 8: Japanese Long-Term projections for Regenerative Medicine Products for Bone and Joint Applications - Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 9: European Recent past, Current & Future Analysis for Regenerative Medicine Products for Bone and Joint Applications - Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
- Table 10: European Long-Term projections for Regenerative Medicine Products for Bone and Joint Applications - Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
